摘要
目的观察冻干重组人脑利钠肽(Lyophilized Recombinant Human Brain Natriuretic Peptide,Lrh-BNP)与米力农(Milrinone)治疗围产期心肌病(peripartum cardiomyopathy,PPCM)的疗效。方法对52例PPCM患者在基础抗心衰治疗上分别应用米力农和Lrh-BNP治疗。结果 Lrh-BNP组总有效率(93.5%)显著高于米力农组(79%);两组治疗前后左心室射血分数(LVEF)、左心室短轴缩短率(Fs)、舒张早期最大充盈速度(E)与舒张晚期最大充盈速度(A)的比值(E/A)、每搏输出量(SV)、心输出量(CO)、24小时尿量、呼吸困难均可得到明显的改善。但Lrh-BNP可以更明显地改善心功能、不增加心率、不降低平均动脉压(MAP)。结论 Lrh-BNP可以更明显地改善PPCM患者心功能,具有更高的临床有效率,且无明显的毒副作用。
Objective To compare the effects between milrinone and lrh-BNP for treating the peripartum cardiomy- opathy heart failure. Methods After treated by routine measure, 52 serious PPCM patients were randomized into two groups, Milrinone group （26 cases） treated with milrinone and Lrh-BNP group treated with Lrh-BNP. Results The total efficient rate in Lrh-BNP group （93.5%） was more higher than that of Milrinone group （79%）. The index of heart func- tion such as LVEF, FS, E/A, SV, CO, 24 hours urine quantity and dyspnea improved after the therapy（P〈0. 05） ,but the effects of Lrh-BNP group was more higher than that of Milrinone group（P〈0. 05）. Conclusion Lrh-BNP can be more efficient in treating PPCM than Milrinone.
出处
《西部医学》
2012年第11期2107-2109,共3页
Medical Journal of West China
关键词
冻干重组人脑钠利肽
围产期心肌病
心力衰竭
药物治疗
Lyophilized recombinant human brain natriuretie peptide
Peripartum cardiomyopathy
Heart Failure
Therapy
